Femme et Homme | 18 ans et plus
- | Pays :
- France
- | Organes :
- Estomac
- Cardia (jonction gastro-œsophagienne)
- | Spécialités :
- Immunothérapie - Vaccinothérapie
- Chimiothérapie
Extrait
CA224-060 - A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) plus Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma